Illumina, Pillar Biosciences announce partnership

September 2023—Illumina and Pillar Biosciences announced a strategic partnership to make Pillar’s suite of oncology assays commercially available worldwide as part of Illumina’s portfolio of oncology products. The companies say the agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques.

“By leveraging Pillar’s targeted sequencing technology alongside Illumina’s state-of-the-art sequencing and bioinformatics solutions, we will enable rapid and focused genomic profiling of tumors, which is essential to facilitate personalized therapy in health care systems across the globe,” Phil Febbo, chief medical officer of Illumina, said in a press statement.

Pillar’s oncology assays can be used on any of Illumina’s sequencers.

Illumina, 858-202-4566
Pillar Biosciences, 508-655-3027